Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | ME2 | P23368 | 8/20 | 0.61 |
| ▸ | ME1 | P48163 | 8/20 | 0.61 |
| ▸ | ME3 | Q16798 | 8/20 | 0.61 |
| ▸ | MAPT | P10636 | 6/20 | 0.60 |
| ▸ | GAA | P10253 | 5/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | CA12 | O43570 | 3/20 | 0.57 |
| ▸ | CA2 | P00918 | 3/20 | 0.57 |
| ▸ | CA9 | Q16790 | 3/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27936730 | 0.86 | TDP1 (0.66) | TDP1ME2ME1ME3MAPT | |
| SCHEMBL17746117 | 0.84 | TDP1 (0.55) | TDP1ME2ME1ME3MAPT | |
| SCHEMBL631962 | 0.83 | ALDH1A1 (0.69) | MAPTLMNAALDH1A1USP2HTT | |
| SCHEMBL5184734 | 0.83 | NPC1 (0.64) | ME2ME1ME3MAPTKDM4E | |
| SCHEMBL5183604 | 0.83 | NPC1 (0.64) | ME2ME1ME3MAPTKDM4E | |
| SCHEMBL7041242 | 0.82 | MAPT (0.68) | TDP1ME2ME1ME3MAPT | |
| SCHEMBL5015647 | 0.82 | AKR1C3 (0.65) | MAPTGAALMNACA12CA2 | |
| SCHEMBL630856 | 0.82 | AKR1C3 (0.65) | TDP1MAPTGAAKDM4ELMNA | |
| SCHEMBL2555420 | 0.82 | AKR1C3 (0.65) | TDP1ME2ME1ME3MAPT | |
| SCHEMBL19059406 | 0.82 | TDP1 (0.62) | TDP1ME2ME1ME3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117756751-A | Preparation method of 4- (4-hydroxyphenyl) -1-piperazine carboxylic acid ethyl ester | 宿迁晨阳医药科技有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-20240076300-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | US | disclosed |
| US-11673902-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | C4 THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230110648-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| WO-2021127561-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2020227156-A1 | ADENOSINE 2 RECEPTOR ANTAGONISTS | NEKTAR THERAPEUTICS (US) | 2020-11-12 | — | — | WO | disclosed |
| WO-2018119441-A9 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| US-9981972-B2 | N-hydroxy bicyclic hydantoin carbamates as tools for identification of serine hydrolase targets | ABIDE THERAPEUTICS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170183353-A1 | N-HYDROXY BICYCLIC HYDANTOIN CARBAMATES AS TOOLS FOR INDETIFICATION OF SERINE HYDROLASE TARGETS | H. LUNDBECK A/S (DK) | 2017-06-29 | — | — | US | disclosed |
| WO-2017093491-A1 | ANTIMYCOTIC TRIAZOLE COMPOUND | PULMOCIDE LIMITED (GB) | 2017-06-08 | — | — | WO | disclosed |
| CN-100400523-C | Substituted piperazines, (1,4) diaza * class and 2, 5-diazabicyclo (2.2.1) heptanes as histamine H1 and/or H3 antagonists or histamine H3 reverse antagonists | GLAXO GROUP LTD (GB) | 2008-07-09 | — | — | CN | disclosed |
| CN-100396668-C | Non-imidazole aryloxypiperidines | ORTHO MCNEIL PHARM INC (US) | 2008-06-25 | — | — | CN | disclosed |
| US-20080139577-A1 | Nitroheteroaryl-containing rifamycin derivatives | CUMBRE PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | disclosed |
| CN-101172981-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-05-07 | — | — | CN | disclosed |
| CN-100366624-C | 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds | OTSUKA PHARMA CO LTD (JP) | 2008-02-06 | — | — | CN | disclosed |
| WO-2008008480-A2 | NITROHETEROARYL-CONTAINING RIFAMYCIN DERIVATIVES | CUMBRE PHARMACEUTICALS INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| CN-101070309-A | Substituted piperazines as histamine H1 and/or H3 antagonists or histamine H3 reverse antagonists, (1, 4) diazabi and 2, 5-diazabicyclo (2.2.1) heptanes | GLAXO GROUP LTD (GB) | 2007-11-14 | — | — | CN | disclosed |
| CN-1726201-A | Substituted piperazines, (1,4) diaza * class and 2, 5-diazabicyclo (2.2.1) heptanes as histamine H1 and/or H3 antagonists or histamine H3 reverse antagonists | GLAXO GROUP LTD (GB) | 2006-01-25 | — | — | CN | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| CN-1468221-A | Non-imidazole aryloxypiperidines | ����-������ҩƷ��˾ | 2004-01-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230110648-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | TDP1 3322/4885ME2 3659/4885ME1 4369/4885 |
| US-20080139577-A1 | Nitroheteroaryl-containing rifamycin derivatives | NRDC, FNTB, RIF1 | TDP1 3377/4885ME2 514/4885ME1 617/4885 |
| US-20240076300-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | TDP1 3322/4885ME2 3659/4885ME1 4369/4885 |
| US-20170183353-A1 | N-HYDROXY BICYCLIC HYDANTOIN CARBAMATES AS TOOLS FOR INDETIFICATION OF SERINE HYDROLASE TARGETS | HPN, BCHE, PRSS1 | TDP1 2137/4885ME2 1099/4885ME1 1583/4885 |
| US-11673902-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | EGFR, ERBB2, ERBB3 | TDP1 3322/4885ME2 3659/4885ME1 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.